Company overview

MolMed S.p.A. is a highly integrated biotech company focused on the identification and development of innovative therapies targeting cancer and AIDS. The company has grown into a leading biotechnology company by building on its unique strengths: scientific expertise and proprietary platforms in the field of molecular medicine.

MolMed began as a spin-off of the Gene Therapy program of the San Raffaele Scientific Institute, which was the first to successfully conduct a gene therapy clinical trial in Europe. The company was founded in 1997 as a joint venture between Boehringer Mannheim (subsequently acquired by Roche) and Science Park Raf, the managing company of the San Raffaele Biomedical Science Park. Initially, MolMed's mission was to supply molecular diagnostics, therapeutic reagents, services and processes necessary for human clinical trials in the area of cell and gene therapy according to GMP (Good Manufacturing Process) standards. Over the first three years, MolMed successfully developed a unique know-how and proprietary technology platform enabling it to develop its own therapeutic products in the field of molecular medicine. In 2001, the company initiated a new phase of growth focusing its mission on the discovery and development of new products in the area of molecular medicine.
At the end of 2001, MolMed acquired Genera S.p.A, the basic research and discovery arm of Science Park Raf in gene therapy and cancer vaccination. The merger of the two companies will combine Genera's research skills and intellectual property in the field of cancer gene therapy with MolMed's specific expertise in ex vivo cell handling and its capability to develop products through clinical trials.

MolMed is developing products targeting Cancer and AIDS, diseases of high social impact which present a high level of unmet therapeutic needs. MolMed's therapies against cancer encompass ground-breaking treatments such as gene therapy, therapeutic vaccination, and vascular targeting.
These therapies have the potential to innovate current cancer treatment by targeting the basis of the disease thus guaranteeing improved specificity and higher quality of life by considerably reducing adverse side effects. MolMed's unique therapeutic approach against AIDS is based on the genetic engineering of patient cells to make them permanently resistant to the attack of the HIV virus.
This approach will help patients who are resistant to conventional treatment and do not tolerate the toxic side effects of long-term multidrug therapy.

www.molmed.it